Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project

Trial Profile

Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PrEP Brasil
  • Most Recent Events

    • 27 Jul 2018 Results evaluating self-reported PrEP adherence and its perceived barriers and facilitators among men who have sex with men and trans-gender women retained though 48 weeks (n=375) presented at the 22nd International AIDS Conference
    • 27 Jul 2018 Results assessing the measures of adherence to HIV pre-exposure prophylaxis (PrEP) among men who have sex with men and trans-gender women (n=354) presented at the 22nd International AIDS Conference
    • 29 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top